Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003962 · ClinicalTrials.gov registry record · Phase 1
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003962 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The verdict
NCT00003962, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have hematologic cancer at risk of relapse.
Interventions
- BIOLOGICAL aldesleukin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-04 |
| Est. Completion | 2000-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003962
The ClinicalTrials.gov registry entry for NCT00003962 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aldesleukin is the first listed.
NCT00003962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003962 about?
NCT00003962 is a clinical study titled "Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 following bone marrow transplantation in treating patients who have hematologic cancer at risk of relapse.
What is the current status of trial NCT00003962?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-04. Estimated completion is 2000-06.
What interventions are being tested in trial NCT00003962?
The interventions under investigation include: aldesleukin (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003962?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.